Loading
A phase 3 trial of Trastuzumab emtansine in her2-positive breast cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer is a phase 3 interventional study registered as NCT06313086 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 442 participants planned, started 2024-03-13 and due to reach its primary completion in 2025-12. Interventions recorded: DP303c, trastuzumab emtansine. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer.
Shares Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer.
Shares Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares Trastuzumab emtansine, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/